Volume 7, Issue 4, August 2019, Page: 73-78
Study of the Exogenous Peptide Effect on the TGF-β1 Expression – A Risk Factor for the Hepatocellular Carcinoma Recurrence
Vadym Shypulin, Department of Internal Diseases, Bogomolets National Medical University, Kyiv, Ukraine
Oksana Stoliarova, Department of Radiology, National Cancer Institute of the MoH of Ukraine, Kyiv, Ukraine
Volodymyr Konovalenko, Department of Oncoimmunology and Antitumor Vaccine Engineering, RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
Oleksiy Tatskyy, Department of Scientific Research, International Institute of Biotherapy, Kyiv, Ukraine
Gennadiy Didenko, Department of Oncoimmunology and Antitumor Vaccine Engineering, RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
Sergii Konovalenko, Department of Scientific Research, International Institute of Biotherapy, Kyiv, Ukraine
Received: Jun. 20, 2019;       Accepted: Jul. 22, 2019;       Published: Aug. 6, 2019
DOI: 10.11648/j.ajbls.20190704.11      View  24      Downloads  18
Abstract
An article deals with the influence of the transforming growth factor beta-1 (TGF-β1) on the carcinogenesis of hepatic cells, as well as attention is given to the role of this factor in the hepatocellular carcinoma (HCC) progression. We monitored two groups of patients: in the treatment group, patients were administered cancer vaccine therapy and anti-relapse immune corrector Arecur® – a complex of exogenous peptides with anti-inflammatory, anti-infective and regenerating properties; in the reference group, patients were not administered immune corrector. The study showed that the cancer vaccine has a positive effect on the activity of T-cell immunity and interleukin-2 expression level. The result of the inclusion of anti-relapse immune corrector Arecur® in the patients’ management regimen was the reduction of TGF-β1 expression. The lower recurrence rate of HCC in the treatment group suggests that Arecur® may prevent possible recurrences and metastasis of HCC by limiting TGF-β1 expression. Future researches of anti-relapse immune correction regimens for patients with hepatic tumours may improve the therapeutic strategy and prevention of the disease progression in the long term. In addition, immune correction using exogenous peptides is likely capable of preventing the malignancy in patients with chronic hepatitis and liver cirrhosis.
Keywords
Hepatitis, TGF-β1, Hepatocellular Carcinoma, Anti-relapse Immune Correction, Exogenous Peptides
To cite this article
Vadym Shypulin, Oksana Stoliarova, Volodymyr Konovalenko, Oleksiy Tatskyy, Gennadiy Didenko, Sergii Konovalenko, Study of the Exogenous Peptide Effect on the TGF-β1 Expression – A Risk Factor for the Hepatocellular Carcinoma Recurrence, American Journal of Biomedical and Life Sciences. Vol. 7, No. 4, 2019, pp. 73-78. doi: 10.11648/j.ajbls.20190704.11
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Giannelli G, Mazzocca A, Fransvea E, Lahn M, Antonaci S. Inhibiting TGF-β signaling in hepatocellular carcinoma. Biochim Biophys Acta. 2011 Apr; 1815 (2): 214-23.
[2]
Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, Matsuzawa Y. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer. 1994 May 1; 73 (9): 2275-9.
[3]
Giannelli G, Villa E, Lahn M. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma. Cancer Res. 2014 Apr 1; 74 (7): 1890-4.
[4]
Huang J., Qiu M, Wan L, Wang G, Huang T, Chen Z, Jiang S, Li X, Xie L, Cai L. TGF-β1 Promotes Hepatocellular Carcinoma Invasion and Metastasis via ERK Pathway-Mediated FGFR 4 Expression. Cell Physiol Biochem 2018; 45: 1690–1699.
[5]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
[6]
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatology 2006; 45: 529–538.
[7]
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
[8]
Akhurst RJ, Hata A: Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012; 11: 790–811.
[9]
Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, Ten Dijke P: TGF-β signalling and liver disease. FEBS J 2016; 283: 2219–2232.
[10]
Shen Y, Wei Y, Wang Z, Jing Y, He H, Yuan J, Li R, Zhao Q, Wei L, Yang T, Lu J: TGF-β regulates hepatocellular carcinoma progression by inducing Treg cell polarization. Cell Physiol Biochem 2015; 35: 1623–1632.
[11]
Giannelli G, Rani B, Dituri F, Cao Y, Palasciano G: Moving towards personalised therapy in patients with hepatocellular carcinoma. Gut 2014; 63: 1668–1676.
[12]
Zheng X, Rumie Vittar NB, Gai X, Fernandez-Barrena MG, Moser CD, et al. (2012) The Transcription Factor GLI 1 Mediates TGFβ1 Driven EMT in Hepatocellular Carcinoma via a SNAI1-Dependent Mechanism. PLOS ONE 7 (11): e49581.
[13]
Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002; 8 (4): 945–954.
[14]
Dongiovanni P., Fracanzani A. L., Fargion S., Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. Journal of Hepatology. 2011; 55 (4): 920–932.
[15]
Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000; 19 (56): 6613–6626.
[16]
Zhang C, Jia X, Bao J, Chen S, Wang K, Zhang Y, Li P, Wan JB, Su H, Wang Y, Mei Z, He C. Polyphyllin VII induces apoptosis in HepG2 cells through ROS_mediated mitochondrial dysfunction and MAPK pathways. BMC Complement Altern Med. 2016 Feb 9; 16: 58.
[17]
Y. Haruyama, H. Kataoka. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2016 Jan 7; 22 (1): 275–283.
[18]
Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J. 2013; 280: 2471–2476.
[19]
Wang SK, Zynger DL, Hes O, Yang XJ. Discovery and diagnostic value of a novel oncofetal protein: glypican 3. Adv Anat Pathol. 2014; 21: 450–460.
[20]
Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ, et al. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014; 8: 177–185.
[21]
Zittermann SI, Capurro MI, Shi W and Filmus J: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res.-2005. 65: 6245–6254.
[22]
A. P. Kuzmenko, G. V. Didenko, G. E. Shpak, G. P. Potebnya. Comparative evaluation of the antitumor efficacy of allogeneic and xenogeneic vaccine modified by protein metabolites of B. subtilis B-7025. Clinical Oncology (2014); 4 (16).
[23]
G. V. Didenko, G. S. Lisovenko, G. P. Potebnya, E. G. Shpak, O. O. Krutz O. P. Kuzmenko, O. P. Karpenko. Efficiency of combined treatment by xenogeneic cancer vaccine and doxorubicin in the experiment. Clinical Oncology (2015); 4 (20).
[24]
Н. V. Didenko, H. S. Lisovenko, V. M. Bazas, N. L. Cheremshenko, I. M. Voyeykova, O. O. Krutz, H. P. Potebnya. Modification of immune response to xenogeneic embryonic proteins by adjuvants of microbial origin. Medical and Clinical Chemistry. 2015; 17. No. 3; 16-22.
[25]
Abenavoli L. Non-alcoholic fatty liver disease and beneficial effects of dietary supplements. World J Hepatol. 2015 Jun 28; 7 (12): 1723–1724.
[26]
Ghorbani Z, Hajizadeh M, Hekmatdoost A. Dietary supplementation in patients with alcoholic liver disease: a review on current evidence. Hepatobiliary Pancreat Dis Int. 2016 Aug; 15 (4): 348-60.
[27]
Koumbi L. Dietary factors can protect against liver cancer development. World J Hepatol. 2017 Jan 28; 9 (3): 119–125.
[28]
Y. Zhou, Y. Li, T. Zhou, J. Zheng, S. Li, H. Li. Dietary Natural Products for Prevention and Treatment of Liver Cancer. Nutrients. 2016 Mar; 8 (3): 156.
[29]
Lee V, Goyal A, Hsu CC, Jacobson JS, Rodriguez RD, Siegel AB. Dietary supplement use among patients with hepatocellular carcinoma. Integr Cancer Ther. 2015 Jan; 14 (1): 35-41.
[30]
O. Lytvynenko, V. Konovalenko, O. Tatskyi, S. Konovalenko, V. Apostolov. Effectiveness of Breast Cancer Recurrences Prophylaxis by Means of Exogenous Peptides: Results of 24 Months Supervision. Rep Cancer Treat.-Volume 2, Issue 1, March, 2018. 39-46.
[31]
Zhao Y, Ju Q, Li G. Tumor markers for hepatocellular carcinoma. Molecular and Clinical Oncology.-Volume 1 Issue 4, July 2013. 593-598.
[32]
Zhou L, Liu J and Luo F: Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol.-2006. 12: 1175–1181.
[33]
Balzarini P, Benetti A, Invernici G, et al: Transforming growth factor-beta 1 induces microvascular abnormalities through a down-modulation of neural cell adhesion molecule in human hepatocellular carcinoma. Lab Invest.-2012. 92: 1297–1309.
[34]
Dong ZZ, Yao DF, Yao M, et al: Clinical impact of plasma TGF-beta 1 and circulating TGF-beta 1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int.-2008. 7: 288–295.
[35]
Peng L., Yuan X., Zhang C., Ye F., Zhou H., Li W., Liu Z., Zhang Y., Pan X., Li G. High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patients. Oncotarget. 2017; 8: 34387-34397.
[36]
Nagaraj NS, Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs. 2010; 19: 77–91.
[37]
Zhang C, Yang M, Ericsson AC (2019) Antimicrobial Peptides: Potential Application in Liver Cancer. Front. Microbiol. 10: 1257.
Browse journals by subject